<DOC>
	<DOC>NCT00097513</DOC>
	<brief_summary>This study is a multicenter, open-label, observational, postmarketing surveillance study that will collect information on the use of Genentech GH preparations to treat GH-deficient subjects with optimal GH dosing during puberty.</brief_summary>
	<brief_title>National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Adolescent boys who are GH deficient and Tanner Stage 2 or greater (testes 3 mL or greater) Adolescent girls who are GH deficient and breast Tanner Stage 2 or greater Current treatment with GH dose of 0.4 to 0.7 mg/kg/wk Ability to keep followup appointments throughout the study Willingness to remain on therapy until epiphyseal closure is achieved Prior enrollment in NCGS Core Study 85036 Treatment with nonGenentech GH preparation Closed epiphyses Active neoplasia Treatment with insulin for diabetes</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Pubertal Growth Hormone Deficiency</keyword>
</DOC>